Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/15733
Title: Combined oral contraceptives and liver cancer
Authors: Ramiro Molina
Luis Martinez
Oriana Salas
Aifredo Dabancens
Tao Yun
Chen Zhi‐Heng
Hu Yong‐Wei
Alvaro Cuadros
Nubia Aristizabal
Baruch Modan
Elaine Ron
Esther Alfandary
J. G. Mati
Patrick Kenya
Alfred Kungu
D. Gatei
Patrick A. Ibeziako
A. A. Abioye
T. A. Junaid
Patrick U. Aghadiuno
Ruben A. Apelo
Julietta R. De LaCruz
Jose Baens
Benjamin D. Canlas
Suporn Silpisornkosol
Tieng Pardthaisong
Boonlong Sivasomboom
Choti Theetranont
Banpot Boosiri
Supawat Chutivongse
Pramuan Virutamasen
Chansuda Wongsrichanalai
Sermsri Sindhvananda
Suporn Koetsawang
Duangdao Rachawat
Orawan Kiriwat
Nivat Chantarakul
P. P. Anthony
David B. Thomas
Janet L. Stanford
Roberta M. Ray
Elizabeth A. Noonan
Susan Holck
Facultad de Medicina de la Universidad de Chile
Shanghai Institute of Planned Parenthood Research
Hospital Universitario
Chaim Sheba Medical Center Israel
University of Nairobi
University of Ibadan
University of the Philippines Manila
Chiang Mai University
Chulalongkorn University
Mahidol University
Exeter North Devon Health Authority
Fred Hutchinson Cancer Research Center
Organisation Mondiale de la Sante
Keywords: Biochemistry, Genetics and Molecular Biology;Medicine
Issue Date: 1-Jan-1989
Citation: International Journal of Cancer. Vol.43, No.2 (1989), 254-259
Abstract: A multi‐national, hospital‐based, case‐control study was conducted to evaluate the possible relationships of steroid contraceptives to 6 neoplasms. Based on data from 122 newly diagnosed cases of primary liver cancer and 802 matched controls, the relative risk of liver cancer in women who had ever used combined oral contraceptives was estimated to be 0.71 (95% Cl 0.4–1.2). No consistent trend in risk with months of use or time since first or last use was observed. Separate analyses also revealed no association between use of combined oral contraceptives and hepatocellular carcinoma (RR = 0.60) or cholangiocarcinoma (RR = 1.22). Most women in this study came from areas in which hepatitis B is endemic and rates of liver cancer are relatively high, and in most cases use of oral contraceptives was of short duration. These results provide no evidence that short‐term use of oral contraceptives enhances risk of liver cancer in countries where the determinants of this disease are similar to those observed in the countries where this study was conducted. Copyright © 1989 Wiley‐Liss, Inc., A Wiley Company
URI: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0024516673&origin=inward
http://repository.li.mahidol.ac.th/dspace/handle/123456789/15733
ISSN: 10970215
00207136
Appears in Collections:Scopus 1969-1990

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.